Abstract: The present disclosure relates to methods, devices, and systems for measuring nitric oxide released from a material. For example, a method of measuring nitric oxide release from a material can include introducing a continuous flow of a carrier gas into a sample holding chamber via a carrier gas inlet at an effective flow rate, introducing an amount of the nitric oxide releasing material into the sample holding chamber via a separate sample inlet to contact the continuous flow of the carrier gas, directing the carrier gas and released nitric oxide out of the sample holding chamber via a nitric oxide outlet toward a nitric oxide detector, and quantifying an amount of released nitric oxide using the nitric oxide detector.

Abstract: The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO.

Abstract: Nitric oxide (NO) generating compositions can include a nitrite component, an acidifying component, and a support material configured to carry one of the nitrite component and the acidifying agent. In some examples, the support material can minimize NO generation prior to addition of an activating amount of a suitable solvent.

Abstract: Compositions and methods of treating conditions in a subject that are responsive to nitric oxide (NO) treatment are disclosed and described. Such compositions can include a combination of a nitric oxide releasing compound, an acidifying agent, and a carrier in amounts that release from about 1 ppm*min/mL to about 500 ppm*min/mL NO based on 1 mL of the composition when measured by releasing NO from the composition for a period of 30 minutes into a flow of substantially inert carrier gas at a flow rate of 1 liter per minute and a pressure of 1 atmosphere, coupled to a chemiluminescence detector.

Abstract: The present disclosure relates to methods, devices, and systems for measuring nitric oxide released from a material. For example, a method of measuring nitric oxide release from a material can include introducing a continuous flow of a carrier gas into a sample holding chamber via a carrier gas inlet at an effective flow rate, introducing an amount of the nitric oxide releasing material into the sample holding chamber via a separate sample inlet to contact the continuous flow of the carrier gas, directing the carrier gas and released nitric oxide out of the sample holding chamber via a nitric oxide outlet toward a nitric oxide detector, and quantifying an amount of released nitric oxide using the nitric oxide detector.

Abstract: Nitric oxide (NO) generating compositions can include a nitrite component, an acidifying component, and a support material configured to carry one of the nitrite component and the acidifying agent. In some examples, the support material can minimize NO generation prior to addition of an activating amount of a suitable solvent.

Abstract: Nitric oxide (NO) generating compositions can include a nitrite component, an acidifying component, and a support material configured to carry one of the nitrite component and the acidifying agent. In some examples, the support material can minimize NO generation prior to addition of an activating amount of a suitable solvent.

Abstract: Medicament containment devices and systems as well as related methods of use for administering a medicament or therapeutic composition or agent to a subject are disclosed and described. In one embodiment, a containment device can include a containment reservoir configured to receive a medicament or therapeutic agent. The containment device can be configured to be secured to a treatment area of a subject and the containment reservoir can be loaded with the medicament or therapeutic agent for administration to the subject in a localized targeted treatment area.

Abstract: A veterinary subject intranasal administration device includes a first support member portion including a septum interface portion sized for insertion into a nasal passage of the veterinary subject; an actuation mechanism connected to the first support member portion; and a fluid conduit having a distal end opposite a supported end, the distal end sized for insertion into the nasal passage of the veterinary subject, the fluid conduit being flexible and configured to receive fluid from a fluid source and discharge the fluid through the distal end into the nasal passage, the distal end of the fluid conduit being unsupported and movable relative to the septum interface portion.

Abstract: A gas-evolving composition delivery system is disclosed, which comprises a pressurized container having a dispenser, and a liquid gas-evolving composition, such as an acidified nitrite solution, within the pressurized container, wherein the pressurized container has an internal pressure sufficient to minimize gas production from the gas-evolving composition while within the container. Also disclosed is a method of stabilizing an acidified nitrite solution comprising loading the solution into a container and sealing the container to be airtight.

Abstract: The present invention relates to compositions and methods useful for immune activation that is effective for eliciting a non-antigen-specific immune response in a subject. An immunomodulator composition can include a therapeutically effective amount of a liquid nitric oxide releasing solution (NORS) for eliciting an immune response in a subject to treat an adverse health condition in the subject.

Abstract: The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO.

Abstract: The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO.

Abstract: A veterinary subject intranasal administration device, and associated systems and methods, are disclosed. The veterinary subject intranasal administration device can include a first support member portion including a septum interface portion sized for insertion into a nasal passage of the veterinary subject; an actuation mechanism connected to the first support member portion; and a fluid conduit having a distal end opposite a supported end, the distal end sized for insertion into the nasal passage of the veterinary subject, the fluid conduit being flexible and configured to receive fluid from a fluid source and discharge the fluid through the distal end into the nasal passage, the distal end of the fluid conduit being unsupported and movable relative to the septum interface portion.

Abstract: The present disclosure relates to methods, devices, and systems for measuring nitric oxide released from a material. For example, a method of measuring nitric oxide release from a material can include introducing a continuous flow of a carrier gas into a sample holding chamber via a carrier gas inlet at an effective flow rate, introducing an amount of the nitric oxide releasing material into the sample holding chamber via a separate sample inlet to contact the continuous flow of the carrier gas, directing the carrier gas and released nitric oxide out of the sample holding chamber via a nitric oxide outlet toward a nitric oxide detector, and quantifying an amount of released nitric oxide using the nitric oxide detector.

Abstract: The present invention relates to compositions and methods useful for immune activation that is effective for eliciting a non-antigen-specific immune response in a subject. An immunomodulator composition can include a therapeutically effective amount of a liquid nitric oxide releasing solution (NORS) for eliciting an immune response in a subject to treat an adverse health condition in the subject.

Abstract: Nitric oxide (NO) generating compositions can include a nitrite component, an acidifying component, and a support material configured to carry one of the nitrite component and the acidifying agent. In some examples, the support material can minimize NO generation prior to addition of an activating amount of a suitable solvent.

Abstract: The present invention relates to compositions and methods useful for immune activation that is effective for eliciting a non-antigen-specific immune response in a subject. An immunomodulator composition can include a therapeutically effective amount of a liquid nitric oxide releasing solution (NORS) for eliciting an immune response in a subject to treat an adverse health condition in the subject.

Abstract: The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the bovine species. The method is particularly effective for protecting a member of the bovine species from infectious disease and treating animals inflicted with infectious disease.

Abstract: The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO.